# 1 T cell responses to SARS-CoV-2 vaccination in people with multiple

# 2 sclerosis differ between disease-modifying therapies

- 3 Asia-Sophia Wolf<sup>\*1</sup>, Anthony Ravussin<sup>\*1</sup>, Marton König<sup>\*2</sup>, Mathias H. Øverås<sup>2</sup>, Guri Solum<sup>1</sup>,
- 4 Ingrid Fadum Kjønstad<sup>1</sup>, Adity Chopra<sup>3,4</sup>, Trygve Holmøy<sup>3,5</sup>, Hanne F. Harbo<sup>2,3</sup>, Silje
- 5 Watterdal Syversen<sup>6</sup>, Kristin Kaasen Jørgensen<sup>7</sup>, Einar Høgestøl<sup>2,3</sup>, Jon Torgils Vaage<sup>3,4</sup>,
- 6 Elisabeth G. Celius<sup>2,3</sup>, Fridtjof Lund-Johansen<sup>3,4</sup>, Ludvig A. Munthe<sup>3,4,8</sup>, Gro Owren
- 7 Nygaard<sup>†2</sup>, Siri Mjaaland<sup>†1</sup>
- 8 \* These authors contributed jointly to this publication
- 9 <sup>†</sup> Joint last authors
- 10
- <sup>1</sup> Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health,
- 12 Oslo, Norway
- <sup>13</sup> <sup>2</sup> Department of Neurology, Oslo University Hospital, Oslo, Norway
- <sup>3</sup> Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- <sup>4</sup> Department of Immunology, Oslo University Hospital, Oslo, Norway
- <sup>5</sup> Department of Neurology, Akershus University Hospital, Lørenskog, Norway
- <sup>6</sup> Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY),
- 18 Diakonhjemmet Hospital, Oslo, Norway
- <sup>7</sup> Department of Gastroenterology, Akershus University Hospital, Lørenskog, Norway
- <sup>8</sup> KG Jebsen Centre for B cell malignancy, University of Oslo, Oslo, Norway
- 21
- 22 Corresponding author: Marton König, MD, PhD, Department of Neurology, Oslo University
- 23 Hospital, PO Box 4956, Nydalen, N-0424 Oslo, Norway (makoni@ous-hf.no).

## 24 Conflicts of interest

- MK reported receiving speaker honoraria from Novartis, Biogen, Merck and Sanofi outside
   the submitted work.
- 27 TH has received speaker honoraria from Biogen, Merck, Novartis, Sanofi, Bristol Myers
- 28 Squibb and Roche, and participated in clinical trials organized by Roche, Merck and Biogen
- 29 EGC has participated in advisory boards and received speaker honoraria from Biogen,
- 30 Janssen, Merck, Novartis, Teva, Roche, Sanofi and Bristol Myers Squibb.
- 31 KKJ has received speaker bureaus from Bristol Myers Squibb and Roche.
- 32
- 33 <u>Running title</u>: Vaccine responses in multiple sclerosis
- 34 Key words: multiple sclerosis, vaccination, SARS-CoV-2, T cells, immunocompromised
- 35

#### 36 <u>Abstract</u>

37 Immune responses in people with multiple sclerosis (pwMS) on disease-modifying therapies 38 (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-39 targeting immunotherapies including anti-CD20 treatments and sphingosine-1-phosphate 40 receptor (S1PR) modulators attenuate antibody responses after vaccination. Evaluation of 41 cellular responses after vaccination is therefore of particular importance in these populations. 42 In this study, we analysed CD4 and CD8 T cell functional responses to SARS-CoV-2 spike 43 peptides in healthy controls and pwMS on five different DMTs by flow cytometry. Although 44 pwMS on anti-CD20 and S1PR therapies had low antibody responses after both 2 and 3 45 vaccine doses, T cell responses in pwMS on anti-CD20 therapies were preserved after third 46 vaccination, even when additional anti-CD20 treatment was administered between vaccine 47 doses 2 and 3. PwMS taking S1PR modulators had low detectable T cell responses in 48 peripheral blood. CD4 and CD8 T cell responses to SARS-CoV-2 variants of concern Delta

and Omicron were lower than to the ancestral Wuhan-Hu-1 variant. Our results indicate the
importance of assessing both cellular and humoral responses after vaccination and suggest
that even in the absence of robust antibody responses vaccination can generate immune
responses in pwMS.

53

#### 54 Introduction

Immune responses to SARS-CoV-2 in immunocompromised individuals have been of intense interest throughout the COVID-19 pandemic. In the absence of vaccination, immunologically vulnerable groups are especially susceptible to severe COVID-19 disease and hospitalisation (reviewed in (1)); after vaccination, reduced responses to SARS-CoV-2 vaccines and potential vaccine failure have been of particular concern.

60 Multiple sclerosis (MS) is an immune-mediated disease characterised by inflammation and 61 demyelination in the central nervous system. Current treatment involves modulation of the 62 immune system to alleviate inflammation. However, some disease-modifying therapies 63 (DMTs) can also impede an effective response to infectious diseases and vaccination 64 (reviewed in (2)). It is unclear whether people with MS (pwMS) are more susceptible to 65 severe COVID-19 disease in the absence of vaccination (3-6); current evidence suggests 66 that this varies depending on DMT usage, where treatment with anti-CD20 drugs presents an 67 increased risk factor (7, 8), as well as neurological disability, comorbidities, and age (6, 8). It 68 is therefore important to establish vaccine effectiveness in pwMS and whether vaccination 69 protects against COVID-19 disease to the same extent as in the general population. Certain 70 DMTs are known to be associated with increased risk of other infections: anti-CD20 drugs 71 such as rituximab, ocrelizumab, and ofatumumab are associated with a range of serious 72 infections, including respiratory tract infections (9, 10); sphingosine-1-phosphate receptor 73 (S1PR) modulators, including fingolimod, ozanimod, and siponimod, which sequester 74 lymphocytes in lymph nodes, are associated with increased risk of herpesvirus infections or

reactivations (11); and natalizumab, an anti-alpha-4 integrin monoclonal antibody (mAb), with

a risk of progressive multifocal leukoencephalopathy (9).

77 The primary focus of many vaccine efficacy studies to date has been the humoral immune 78 response (12, 13). Many DMTs, particularly anti-CD20 drugs, target B cells and people on 79 such treatments have reduced or non-existent antibody responses after vaccination (14-18); 80 pwMS on fingolimod have been found to have significantly reduced antibody responses (14, 81 19), By contrast, pwMS taking other DMTs including natalizumab (20, 21), cladribine (an 82 adenosine mimic which triggers lymphocyte apoptosis) (22), and alemtuzumab (an anti-83 CD52 mAb that depletes T and B cells) (23) appear to have antibody responses comparable 84 to untreated control groups. 85 Nevertheless, it is unclear if vaccine-specific T cell responses are impaired. Several studies 86 have looked at cellular responses to SARS-CoV-2 spike peptides in pwMS after two doses of 87 SARS-CoV-2 vaccine (16, 21, 24-26) and found that IFN-y+T cell responses were 88 detectable in many, though not all, patients on a variety of DMTs. One exception was pwMS 89 treated with fingolimod (26), where T cell responses were significantly attenuated. Although 90 not all individuals on anti-CD20 therapies developed T cell responses, it further appears that 91 T cell responses and antibody titres are not well correlated, and so a lack of antibody 92 response is not in itself indicative of a failed response to vaccination (27). Additionally, data 93 on the effect of a third vaccine dose on both antibody levels and T cell responses are mixed; 94 some studies suggest no effect of additional vaccination on either humoral or cellular 95 immune responses (28), whereas others find boosted responses (29, 30). 96 The time period between receiving a dose of DMT and vaccination varies between DMTs. 97 Fingolimod, for example, is taken daily, whereas anti-CD20 treatments are administered at 98 six-month intervals, with a clear impact of this interval on the humoral response. An 99 increased gap between administration of anti-CD20 therapies and vaccination is associated 100 with stronger antibody responses (15, 27, 31, 32), which may be beneficial during 101 vaccination but can also lead to interruptions in ongoing treatment of MS or undesirable

delay in vaccine schedules. It is therefore of interest to establish what effect ongoing DMT
 treatment has on vaccine responsiveness during both the primary vaccine course and for
 subsequent boosters.

105 Recent register studies indicate that pwMS treated with high efficacy DMTs, including 106 alemtuzumab, natalizumab, cladribine, S1PR modulators, and anti-CD20 therapies, have the 107 best long-term outcomes for reduced worsening of disability and relapse outcomes (33, 34). 108 Although for safety reasons alemtuzumab is rarely given to newly diagnosed patients, many 109 people have been treated with this induction therapy during the last decade and comprise an 110 important subset of pwMS. This study therefore focused on the cellular response to these 111 five therapies that are among the most likely to be the treatments of choice for future pwMS. 112 The aim of this study was to investigate IgG antibody binding to the receptor binding domain 113 (RBD) on the spike protein of SARS-CoV-2 as well as functional spike-specific CD4 and CD8 114 T cell responses from pwMS on five different DMTs and a healthy control group after two 115 doses of SARS-CoV-2 vaccine. We also investigated whether a third vaccine dose improved 116 the humoral and/or cellular responses in individuals treated with rituximab or fingolimod who 117 had impaired IgG anti-spike RBD antibody responses after two vaccine doses.

118

## 119 <u>Results</u>

120 A cohort of pwMS living in Oslo or Akershus, Norway, who were treated with DMTs prior to 121 the beginning of the COVID-19 pandemic were recruited as part of an ongoing population-122 based study of vaccine responses in pwMS in Norway (NevroVax) (15, 29). Cellular samples 123 were collected from a subset of individuals on different DMTs (fingolimod, rituximab, 124 cladribine, natalizumab and alemtuzumab) both before and after the primary course of 2 125 vaccine doses in April-July 2021 (Supplementary Figure 1). Healthy controls were recruited 126 from among healthcare workers at Diakonhjemmet Hospital and Akershus University 127 Hospital. Rituximab- and fingolimod-treated individuals who had low antibody responses after

vaccination were offered a 3rd vaccine dose in the summer of 2021 (EudraCT Number: 2021-128 129 003618-37, see Methods), before recommendations for booster vaccines in Norway were 130 changed in September of that year to recommend a 3<sup>rd</sup> dose for all immunocompromised 131 individuals. The characteristics of this cohort are described in Table 1 according to DMT, 132 including age, sex, time since last drug administration, and vaccine type (primarily the mRNA 133 vaccines BNT162b2 (Comirnaty, Pfizer-BioNTech) and mRNA-1273 (Spikevax, Moderna); 134 see Methods for further details). Breakthrough COVID-19 infections >14 days after 135 vaccination are shown for each group (n=29 across all DMTs and healthy controls). 136 Infections were predominantly contracted between November 2021-February 2022, 137 representing a mixture of Delta and Omicron VOC infections. None of the individuals were 138 hospitalised or died. 139 DMTs vary based on mechanism of action and cellular target. We therefore assessed the 140 effect of each DMT on the lymphocyte, CD4 and CD8 T cell frequency and function by flow 141 cytometry (Figure 1). The full flow cytometry gating strategy is shown in Supplementary 142 Figure 2. Compared to healthy controls, pwMS on DMTs did not show altered frequencies of 143 CD3+ lymphocytes except for fingolimod-treated individuals, who had significant reductions 144 in the CD3+ cell populations (Figure 1A) (proportion of CD3+ live lymphocytes in fingolimod-145 treated: median, 46.9%; IQR, 44.9%; healthy controls: median, 66.8%; IQR, 11%). 146 Additionally, fingolimod-treated individuals had sharply reduced CD4+T cell populations 147 (fingolimod-treated: median, 19.2%; IQR, 26.0%; healthy controls: median, 63.1%; IQR, 148 14.1%) and a concomitant increase in CD8+ T cells (Figure 1B and Supplementary Figure 3). 149 The graphs show frequencies from the post-vaccination time point; however, the cell 150 population frequencies for individuals were consistent before and after vaccination. The 151 CD4:CD8 T cell ratio did not correlate with antibody responses in fingolimod-treated 152 individuals, and people with less distorted ratios of T cells did not have improved antibody 153 titres, which were low throughout the group (data not shown).

154 Antibody and T cell responses were measured to assess the immune response to two doses of vaccine. Samples taken 3 weeks (median 20.5 days) after the 2<sup>nd</sup> vaccine dose were 155 156 assayed for antibody binding activity (Figure 1C). IgG anti-spike RBD responses were 157 classified as negative (<5 BAU/ml), very weak positive (5-20 BAU/ml), weak positive (20-200 158 BAU/mI), and positive (>200 BAU/mI) and are indicated on the graph for reference. All 159 healthy controls and individuals treated with alemtuzumab, cladribine and natalizumab had 160 strong antibody titres, predominantly in the 'positive' range (median per group: healthy 161 control, 1166 BAU/ml; alemtuzumab, 5591 BAU/ml; cladribine, 3081 BAU/ml; natalizumab, 162 3625 BAU/ml). However, individuals treated with fingolimod or rituximab had poor antibody 163 responses after two vaccine doses (median: fingolimod, 2.5 BAU/ml; rituximab, 0.5 BAU/ml 164 (below the level of detection for this assay)). 165 T cell responses were assessed using activation-induced marker (AIM) assays and 166 measured by flow cytometry (see Supplementary Figure. 2 for gating). Peripheral blood 167 mononuclear cells (PBMCs) were stimulated with SARS-CoV-2 spike peptides and CD4 T 168 cell activation was measured by CD40L and TNF- $\alpha$  coexpression (Figure 1D) before (V0, 169 baseline) and 2 weeks after (V2) vaccination. Samples were taken from the same individuals 170 at both time points wherever possible, indicated by paired dots. There was a significant 171 increase in the spike-specific CD4 T cell response after vaccination in the healthy controls 172 and alemtuzumab-treated patients. This suggested that most of the alemtuzumab-treated 173 pwMS had reconstituted their immune system within the time since last treatment, which was 174 more than three years for most patients. Responses were highly heterogeneous and did not 175 reach statistical significance in the other DMT groups. More than half (10/18) of the 176 fingolimod-treated group had too few CD4 T cells in our assay to accurately measure 177 activation responses and were excluded from the analysis as we had too few CD4+ events to 178 calculate the percent response. CD8 T cell responses (Figure 1E) producing IFN-y and TNF-179  $\alpha$  varied between individuals. Of interest, IFN- $\gamma$ + and TNF- $\alpha$ + spike-specific CD8+ T cell 180 responses from fingolimod-treated individuals negatively correlated with higher proportions of

181 CD8+ T cells (i.e. individuals with more skewed CD4/CD8 ratios also had fewer cytokine
182 producing CD8 T cells), although this did not reach statistical significance (Supplementary
183 Figure 3I).

184 As the fingolimod- and rituximab-treated individuals had poor antibody responses, these 185 patients received a third dose of vaccine (see Methods) (Figure 2). Individuals treated with 186 rituximab did not show significant improvements in IgG anti-spike RBD after a third vaccine 187 dose (Figure 2A), although the overall responses and number of responders increased 188 (median and IQR at V2, 1.3 and 18.3 BAU/ml; at V3, 2.0 and 665.5 BAU/ml; 13/43 (30.2%) 189 individuals had >5 BAU/ml titres after 2 vaccine doses, increasing to 27/61 (44.3%) after 3 190 vaccine doses), suggesting that some, though not all, individuals improved their antibody 191 responses after repeated vaccination. However, the number of patients that were positive 192 (>200 BAU/ml) was significantly increased from 5/43 after 2 doses to 19/61 after 3 doses 193 (two-tailed p=0.0320, Fisher's exact test). Moreover, a significant proportion of individuals 194 had detectable spike-specific CD4 and CD8 T cell responses (Figure 2B-C), demonstrating 195 that rituximab treatment does not inhibit T cell responses to the same extent as antibody 196 responses.

197 The same effect was not seen for people treated with fingolimod. After a third vaccine dose, 198 fingolimod-treated patients showed no significant increase in IgG anti-spike RBD (Figure 2D), 199 and generally had even lower antibody responses than the rituximab-treated group, with no 200 patients reaching the 'positive' response classification of >200 BAU/ml (median and IQR at 201 V2, 2.1 and 5.35 BAU/ml; at V3, 8.0 and 33.5 BAU/ml). Despite an increase in weak 202 responders (20-200 BAU/ml), this was not statistically significant (1/13 individuals had weak 203 responses after V2 compared to 7/21 after V3; two-tailed p=0.1164, Fisher's exact test). 204 Spike-specific CD4 and CD8 responses also showed no significant response, suggesting 205 that fingolimod has a major impact on measurable T cell responses in blood as well as 206 antibody levels. We did see a small but statistically significant CD8 T cell response 207 (p=0.0429) to influenza (flu) peptides compared to the unstimulated control, suggesting that

existing T cell responses, possibly generated prior to beginning fingolimod treatment, are
maintained over time.

210 61.4% (51/83) of fingolimod- or rituximab-treated patients received an influenza vaccine 211 between September 2020 and February 2021. However, influenza-specific T cell responses 212 did not significantly differ between individuals who had received a seasonal influenza 213 vaccination during the previous winter (2020-21) and those who had not. This suggested that 214 T cell responses generated via previous vaccination or influenza infections prior to the 215 COVID-19 pandemic were still detectable in these patients. There was a weak but significant 216 positive correlation between CD4 responses to SARS-CoV-2 spike and CD4 responses to 217 influenza peptides in rituximab-treated patients, suggesting individual differences to vaccine 218 antigens in general (Supplementary Figure 4A). T cell responses to EBV and CMV peptides 219 were higher than responses to the vaccine peptides, which represents the difference 220 between vaccination and latent viral infection. In rituximab-treated individuals we saw strong 221 CMV-specific CD4 and CD8 T cell responses (p=0.0005 and p<0.0001 respectively, 222 Wilcoxon tests) (Figure 2B) and EBV-specific CD8 T cell responses (p<0.0001) (Figure 2C). 223 However, there was no correlation between CD4 T cell responses to spike and CMV in 224 rituximab-treated patients, (Supplementary Figure 4B), CD4 and CD8 T cell responses to 225 spike (Supplementary Figure 4C), or CD4 responses and antibody responses 226 (Supplementary Figure 4D), consistent with other studies showing low concordance between 227 these measures of immune responsiveness (27). 228 The administration interval of DMTs varies by drug, as described in Table 1. In the course of 229 this study, patients taking rituximab received treatment according to their individual 230 schedules. All patients received rituximab prior to the baseline (V0) sample and completed

the initial two-dose vaccine course without further rituximab infusions. Between the second

and third vaccine doses, approximately half (30/62) of the patients received another dose of

rituximab (median time 8.43 weeks before V3, range 1.86-19.7 weeks). We hypothesised

that this rituximab dosage impaired the ability to respond to vaccination. Antibody and T cell

235 responses in these two groups were therefore compared (Figure 3). There was no significant 236 difference in IgG anti-spike RBD between these two groups after the second vaccine dose 237 (V2), but after a third vaccine dose (V3) individuals who had recently received rituximab had 238 significantly lower antibody activity (Figure 3A) than those who had not (p=0.023, unpaired t 239 test). However, there was no such difference between the T cell responses of the two groups 240 (Figure 3B-C). Comparing the spike-specific responses between groups showed no 241 difference in CD4 (p=0.998, unpaired t test) or CD8 T cell activation (p=0.545), suggesting 242 that T cell responses are not affected by re-administration of rituximab after the primary 243

244 Finally, the question of whether vaccination confers protection against SARS-CoV-2 variants 245 of concern (VOC) has been of particular concern since the initial emergence of the Alpha 246 (B.1.1.7) variant and subsequent Delta (B.1.617.2) and Omicron (B.1.1.529/BA.1-5) variants. 247 Mutations in the spike region of these variants are thought to reduce the ability of vaccine-248 generated antibodies to recognise these variants and potentially to reduce protection against 249 them. To measure how T cell responses from vaccination were affected, we assessed CD4 250 and CD8 T cell responses to the mutated peptides of these three variants (Figure 4). PBMCs 251 from triple-vaccinated rituximab-treated patients were stimulated as before with only the 252 mutated peptide regions from the Alpha, Delta, or Omicron variants, as well as the 253 homologous peptides for each variant from the original Wuhan-Hu-1 sequence). The location 254 and number of mutated peptides (34, 32 and 83 peptides for Alpha, Delta, and Omicron 255 respectively) are shown in Figure 4A. There were no significant differences in CD4 T cell 256 responses to the Alpha variant compared to the homologous Wuhan-Hu-1 sequence, but 257 significantly reduced responsiveness to the mutated peptides of both the Delta (p=0.047, 258 Wilcoxon t test) and Omicron variants (p=0.0028) (Figure 4B). Although CD8 T cell 259 responses were reduced, particularly for the Delta VOC, these differences did not reach 260 significance (Figure 4C).

261

vaccine course.

# 262 Discussion

263	Older and immunocompromised individuals are particularly at risk of severe COVID-19
264	disease. Vaccine efficacy in immunocompromised individuals is therefore important to
265	understand, particularly as many countries including Norway (35) have achieved high
266	vaccine coverage and have since lifted many or all infection-limiting measures such as social
267	distancing. However, SARS-CoV-2 variants continue to circulate, and vulnerable groups may
268	still be at risk of severe disease. These data show that pwMS treated with alemtuzumab,
269	cladribine, and natalizumab have robust humoral and CD4 and CD8 T cell responses after
270	two vaccine doses, in agreement with other studies (3, 14, 20, 22, 25). However, individuals
271	treated with fingolimod and rituximab have strongly reduced antibody responses compared
272	with both healthy controls and pwMS taking other DMTs. Upon receipt of a third vaccine
273	dose, both treatment groups showed small increases in IgG anti-spike levels and a
274	significantly increased percentage of patients developed high responses (>200 BAU/mI) in
275	the rituximab treated group, demonstrating that some individuals were capable of increasing
276	B cell responses. This finding was also found in a larger study where improved IgG anti-spike
277	responses were found after third vaccination (29). Moreover, triple-vaccinated rituximab-
278	treated individuals demonstrated both CD4 and CD8 T cell responses against SARS-CoV-2
279	spike peptides. These T cell responses were not reduced even when individuals received
280	rituximab between their second and third vaccine doses, suggesting that although re-
281	administration of anti-CD20 drugs does impair humoral responses, cellular responses are
282	preserved.
283	Additionally, we observed strong CD4 and CD8 T cell responses to the herpesviruses CMV

and EBV in pwMS, suggesting that specific T cell responses against antigens from long-term
latent infections are present. T cell activation against other vaccine antigens such as
influenza were comparable to the SARS-CoV-2 spike-specific responses, and rituximabtreated individuals showed a positive correlation between spike-specific and flu-specific
responses. This suggests that vaccine responsiveness varies by individual but is not

necessarily associated with T cell responses to other infections such as CMV. Immune responses may also differ based on whether individuals were already using DMTs at the time of antigen exposure, which may affect the magnitude of the immune response, as well as the availability and duration of antigen seen during vaccination or acute infection compared to chronic infections.

294 In pwMS treated with fingolimod, a third vaccine dose did not appear to improve either the 295 antibody or T cell responses. As fingolimod is taken daily, the fluctuations in B cell counts 296 seen in individuals taking anti-CD20 drugs are not seen (36). The reduction in peripheral 297 lymphocyte and CD4 T cell counts we observed here was consistent in individuals at 298 different sampling points, suggesting that the administration of fingolimod causes lymphocyte 299 sequestration to different extents for each individual. Although antibody titres were strongly 300 reduced for all fingolimod-treated patients, we observed that individuals with less skewed 301 CD4:CD8 T cell ratios had stronger spike-specific CD8 T cell responses, suggesting that 302 people with higher circulating CD4 T cell frequencies are more likely to generate measurable 303 and potentially protective cellular responses.

304 Nevertheless, pwMS receiving fingolimod do not appear to be at higher risk of severe

305 COVID-19 or hospitalisation than the general population prior to vaccination (7, 37).

306 Fingolimod has been found to reduce proinflammatory cytokine release from dendritic cells

307 and monocytes (38) which may reduce detrimental uncontrolled inflammation associated with

308 severe COVID-19 disease (39). Additionally, as lymphocytes are sequestered rather than

309 destroyed by S1PR modulators (40), failure to detect T cell responses in peripheral blood

310 may not fully reflect the extent of the total T cell response, and non-circulating cellular

responses induced by vaccination may be present in the lymph nodes or other secondary

312 lymphoid organs.

Several large-scale studies have found that pwMS on fingolimod or ocrelizumab are at higher risk of SARS-CoV-2 infection after vaccination than the general population or pwMS on other DMTs (41-43), possibly reflecting the role of circulating antibodies in preventing infection. 316 However, the severity of these infections is still unclear, and where cases could be followed 317 on an individual level, there were no deaths from COVID-19 (42, 43). Further research has 318 found that, even after vaccination, pwMS on anti-CD20 drugs were at higher risk of 319 hospitalisation but not death; this risk was not seen with other DMTs including S1PR 320 modulators (44). In our study, 29 individuals across all DMTs contracted SARS-CoV-2 after 321 vaccination and none of these were hospitalised or died. Further large-scale studies are 322 required to determine vaccine protection against severe disease and death in pwMS and 323 particularly patients treated with anti-CD20 drugs and S1PR modulators. 324 The emergence of SARS-CoV-2 VOC has further complicated the question of vaccine 325 efficacy and protection. Neutralising antibodies against the Delta and Omicron VOCs have 326 been found to be sharply reduced compared to the original Wuhan-Hu-1 strain (45), while T 327 cell responses are more heterogeneous and show wide cross-reactivity to other human 328 coronaviruses as well as between variants (46-48). In triple-vaccinated rituximab-treated 329 individuals we found that CD4+ T cell responses to both the Delta and Omicron VOCs were 330 reduced compared to WT, suggesting that although T cells are responsive to the mutated 331 VOC regions, vaccine-generated T cell-mediated protection may be reduced. However, 332 these mutated regions cover only a fraction of the spike peptide sequences and further work 333 is needed to determine how these mutations affect T cell vaccine responses. 334 We found no correlation between any combinations of antibody titre, CD4 T cell responses, 335 or CD8 T cell responses, and therefore using only one of these parameters as an indication 336 of immune responsiveness cannot give a full picture of vaccine efficacy. Although the 337 correlates of protection against SARS-CoV-2 infection and severe COVID-19 disease are still 338 unclear and the relative roles of antibody-mediated virus neutralisation and T cell-dependent 339 protection are still being extensively studied (49-51), analysis of cellular responses in 340 addition to antibody titres can give a better understanding of whether immunosuppressed 341 individuals are likely to require additional protective measures. Further follow up studies are 342 required to determine whether T cell responses in the absence of antibody titres, such as

seen in our rituximab-treated population, are protective against severe disease, but the

344 current evidence supports the contention that T cell immunity is sufficient.

- 345 One limitation of this work is a lack of longitudinal sampling to measure changes in CD4 and
- 346 CD8 T cell responses between the second and third vaccine for the rituximab- and
- 347 fingolimod-treated patients. The question of whether repeated vaccination with antigens from
- the Wuhan-Hu-1 variant can prevent disease from successive VOC remains to be seen.
- In summary, we found that pwMS on DMTs that inhibit antibody responses are still capable
- of mounting T cell responses comparable with healthy controls, and furthermore that
- 351 continued administration of the widely used anti-CD20 drug rituximab between the primary
- 352 vaccine course and subsequent vaccine doses does not impede cellular responses. Further
- analyses of the efficacy and durability of cellular responses, and well as the impact of
- 354 additional vaccination, are needed to better understand how vaccines protect against severe
- 355 disease in immunocompromised individuals.
- 356

## 357 Methods

### 358 Participant recruitment and ethical approvals

359 All patients from the Norwegian MS registry (n=12000) in 2021 were invited to participate in 360 the humoral arm of the NevroVax study. A subgroup of patients from Oslo University Hospital 361 on the DMTs alemtuzumab, cladribine, natalizumab, fingolimod and rituximab (c. n=10 per 362 DMT) were recruited to provide PBMC samples, along with all patients who lacked antibody 363 responses after 2 vaccine doses (considered at the time to be <70 arbitrary units (AU)/ml by 364 ELISA). Individuals from Oslo University Hospital, Akershus University Hospital and 365 Haukeland University hospital with low humoral responses subsequently received a third 366 vaccine dose and those treated at Oslo University Hospital or Akershus University Hospital 367 comprised the fingolimod- and rituximab-treated individuals at V3. Healthy controls were

368 recruited among healthcare workers from Diakonhjemmet Hospital and Akershus University

- 369 Hospital and samples were stored in the Oslo University Hospital biobank.
- 370 Vaccination and inclusion in vaccination trial
- 371 PwMS were vaccinated as per guidelines of the Norwegian Corona Vaccination Program
- 372 where immunocompromised individuals and healthcare workers (who participated here as
- 373 healthy controls) were high priority. Vaccines were administered according to the
- 374 manufacturers' recommendations and health administration advice at the time, ranging from
- three weeks between first and second doses for mRNA-1273 and 6-10 weeks for BNT162b2.
- 376 Some individuals received first doses of ChAdOx1-S (Vaxzevria, AstraZeneca), the
- 377 distribution of which was subsequently discontinued in Norway in March 2021, and received
- 378 second doses of BNT162b2. Individuals who had a COVID-19 infection before or during the
- 379 course of vaccination were excluded from further analyses. Individuals who failed to
- 380 seroconvert to IgG anti-spike (RBD) after the standard two doses were invited to participate
- in a vaccination trial to receive a third dose of mRNA-1273 or BNT162b2 outside the
- framework of the Norwegian Corona Vaccination Program (EudraCT Number: 2021-003618-
- 383 37). Further patients included in this study after 1<sup>st</sup> September 2021 received third dose
- 384 vaccines following revised guidelines in the Norwegian Corona Vaccination Program (where
- all immunocompromised adults were advised to receive a third dose).
- 386 Sample collection
- 387 Venous blood for PBMC isolation was collected at Oslo University Hospital into BD
- 388 Vacutainer CPT tubes with sodium citrate. Tubes were centrifuged for 20 minutes at 1600xg
- to isolate PBMCs, which were then pipetted into fresh tubes, washed twice with RPMI, and
- frozen in 90% foetal calf serum (FCS) (Gibco, Thermo Fisher) with 10% dimethyl sulfoxide
- 391 (DMSO, Sigma Aldrich) in liquid nitrogen for future use.

# 392 <u>T cell stimulation and flow cytometry</u>

393 Cryopreserved PBMCs were thawed in RPMI, washed thrice to remove residual DMSO, and 394 counted. Cells were plated into 96-well U-bottomed plates at 200,000 cells per well and 395 stimulated for 24 hours in RPMI culture media containing 10% FCS, 1mM sodium pyruvate 396 (Gibco, Thermo Fisher), 1x MEM NEAA (Gibco), 50nM 1-thioglycerol and 12ug/ml 397 gensumycin. GolgiPlug (BD Biosciences) containing brefeldin A was added after 2 hours of 398 stimulation until the end of the incubation. Cells were stimulated with peptide pools: 399 PepTivator SARS-CoV-2 Prot S covering the immunodominant sequence domains of the 400 spike glycoprotein from the SARS-CoV-2 (Wuhan-Hu-1 variant), EBV Consensus, and CMV 401 pp65 pool (used according to the manufacturer's recommendations at 0.75nmol/ml, all 402 Miltenvi Biotec) and pooled pan-influenza peptides for HLA class I and II (final concentration 403 1µq/ml) (GenScript). Peptide pools for mutated SARS CoV-2 Spike are outlined in the next 404 paragraph. Cytostim (Miltenyi Biotec) was used as a positive control according to the 405 manufacturer's recommendation. 406 After 24 hours, cells were centrifuged at 500xg for 5 minutes, the supernatant discarded, and 407 cells resuspended in FACS buffer (1% FCS in PBS). Cells were centrifuged again and the 408 supernatant removed. Cells were incubated with 10µl surface antibody cocktail (anti-human 409 CD3-BV605 (clone SK7) (BD Biosciences), CD4-eFluor 450 (OKT-4), CD8-AF488 (OKT-8), 410 and Fixable Live/Dead Near-IR (1:1000 dilution) (all ThermoFisher)) for 30 minutes at 4°C. 411 washed in FACS buffer, then fixed in Fix/Perm (BD Biosciences) for 20 minutes at room 412 temperature. Cells were then washed twice with PermWash (BD Biosciences) and incubated 413 with 10µl intracellular antibody cocktail (anti-human IFN-y-BV711 (clone 4S.B3), CD40L-414 BV510 (24-31) (both BioLegend), TNF-α-PE (Mab11), CD69-APC (FN50) (both BD 415 Biosciences)) for 30 minutes at room temperature. Cells were finally washed with PermWash

and resuspended in 200ul FACS buffer for analysis by flow cytometry within 24 hours.

417 Cells were acquired on a BioRad ZE5 flow cytometer and analysed with FlowJo<sup>™</sup> v.10.7

418 Software (BD Life Sciences).

#### 419 Variants of Concern and mutated peptide sequences

420	Three PepTivator SARS-CoV-2 VOC spike protein Mutation Pools and the three
421	corresponding spike protein WT Reference Pools (all Miltenyi Biotec) were used at a final
422	concentration of 0.75 nmol/ml per the manufacturer's recommendation. Prot_S B.1.1.7
423	Mutation Pool (cat. no. 130-127-844) included 34 peptides from 10 mutations: deletion 69,
424	deletion 70, deletion 144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H. The
425	corresponding non-mutated peptide pool control was Prot_S B.1.1.7 WT Reference Pool
426	(cat. no. 130-127-841).
427	Prot_S B.1.617.2 Mutation Pool (cat. no. 130-128-763) included 32 peptides from 10
428	mutations: T19R, G142D, E156G, deletion 157, deletion 158, L452R, T478K, D614G,
429	P681R, and D950N. This subvariant lacks the E484Q mutation. The non-mutated peptide
430	pool control was Prot_S B.1.617.2 WT Reference Pool (cat. no. 130-128-761).
431	Prot_S B.1.1.529/BA.1 Mutation Pool (cat. no. 130-129-928) included 83 peptides from 37
432	mutations: A67V, H69 deletion, V70 deletion, T95I, G142D, V143 deletion, Y144 deletion,
433	Y145 deletion, N211 deletion, L212I, insertion 214EPE, G339D, S371L, S373P, S375F,
434	K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H,
435	T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.
436	The non-mutated peptide pool control was Prot_S B.1.1.529/BA.1 WT Reference Pool (cat.
437	no. 130-129-927).
438	Antibody quantification

Semiquantitative measurement of antibodies to full-length spike protein (Spike-FL) and the receptor-binding domain (RBD) from SARS-CoV-2 was performed using a multiplexed beadbased assay as described in (52). Polymer beads with fluorescent barcodes were coupled to successively to neutravidin (ThermoFisher) and biotinylated viral antigens to generate beadbased protein arrays. Sera were diluted 1:100 in assay buffer (PBS, 1% Tween-20, 10ug/ml D-biotin, 10 µg/ml neutravidin, 0.1% sodium azide). Diluted sera were incubated with beadbased arrays in 384 well plates for 30 minutes at 22°C at constant agitation, washed three

446	times in PBS/1% Tween-20 (PBT) and labelled with R-Phycoerythrin (R-PE)-conjugated
447	goat-anti-human IgG (Jackson Immunoresearch). For measurement of neutralizing
448	antibodies, the beads were pelleted after incubation with serum and labelled successively
449	with digoxigenin-conjugated human ACE2 and mouse monoclonal anti-dixogigenin (Jackson
450	Immunoresearch), which was conjugated in-house to R-PE. The beads were analyzed with
451	an AttuneNxT flow cytometer (ThermoFisher), and raw data (fcs.3.1) were analyzed in
452	WinList 3D (Verity Softwarehouse). The median R-PE fluorescence intensity (MFI) of each
453	bead subset was exported to Excel. The MFI of beads coupled with viral antigens was
454	divided by that measured on beads coupled with neutravidin only (relative MFI, rMFI). A total
455	of 979 pre-pandemic sera and 810 sera from COVID-19 convalescents were analyzed to
456	establish cutoffs for seropositivity. A double cutoff of rMFI >5 for anti-RBD and anti-Spike FL
457	yielded a specificity of 99.7% and a sensitivity of 95% (53). Serum from an individual who
458	had received three doses of the Pfizer/BioNTech anti-COVID-19 vaccine was used as
459	standard to convert signals to binding antibody units per milliliter (BAU/ml).

#### 460 Statistics and analysis

- 461 Statistical analyses were performed using GraphPad Prism v.9 for Windows, GraphPad
- 462 Software. Two-tailed p values are shown. For analysis of functional markers (CD40L+ TNF-
- 463  $\alpha$  + CD4 T cells and IFN- $\gamma$  + TNF- $\alpha$  + CD8 T cells), data from FACS plots with fewer than 1000

464 CD4 or CD8 T cells were excluded.

## 465 <u>Study approval</u>

- 466 The study was approved by the Norwegian South-Eastern Regional Ethical Committee
- 467 (Reference numbers 200631, 235424, 135924, and 204104), and the Norwegian Medicines
- 468 Agency (EudraCT Number: 2021- 003618-37). All participants gave written, informed
- 469 consent prior to inclusion in this study.
- 470

471

## 472 <u>Author contributions</u>

LAM and SM conceived and designed the study. A-SW drafted the paper. AR, MK, LAM, TH,
GON, and SM contributed to drafting the paper. A-SW, AR, GS, IFK, and AC performed
experiments. A-SW, AR, MK, GS, IFK, FL-J, GON, LAM, and SM analyzed and interpreted
data. MHØ, AC, TH, HFH, EH, JTV, and EGC contributed to data analysis and interpretation.
MK, GON, MHØ, SWS, KKJ, JTV, FL-J, and LAM organized the collection of samples and
information from the cohorts. All authors contributed to and approved the final manuscript.

479

# 480 Acknowledgements

481 The authors would like to thank Ingrid Egner, Katrine Persgård Lund, Viktoriia Chaban, and

482 Julie Røkke Osen at the Department of Immunology, Oslo University Hospital for biobanking

and technical help. We would also like to thank the participants in the NevroVax study and

484 staff at Diakonhjemmet Hospital and Akershus University Hospital for donating blood

samples, as well as the staff at Oslo University Hospital for taking the samples. This study

486 was supported by the Norwegian Institute of Public Health, the Norwegian Ministry of Health

through a program for corona vaccination surveillance, the Odd Fellows Foundation, the

488 Sanofi Research Fund for MS, the Norwegian MS Society, and the Research Council of

489 Norway (RCN) Covid (312693), LAM, SM; a KG Jebsen Foundation (grant 19), LAM; the

490 Coalition for Epidemic Preparedness Innovations (CEPI), LAM, SM, JTV, FL-J; and the

491 University of Oslo and Oslo University Hospital, LAM, FL-J, JTV.

492

493 <u>Bibliography</u>

Brodin P. Immune determinants of COVID-19 disease presentation and severity.
 Nature Medicine. 2021;27(1):28-33.

496	2.	Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple
497	scler	osis patients. Journal of Neuroimmunology. 2021;356:577599.

- 498 3. Hada M, Mosholder AD, Leishear K, Perez-Vilar S. Systematic review of risk of
- 499 SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple
- 500 sclerosis. Neurol Sci. 2022:1-11.
- 501 4. Sharifian-Dorche M, Sahraian MA, Fadda G, Osherov M, Sharifian-Dorche A,
- 502 Karaminia M, et al. COVID-19 and disease-modifying therapies in patients with
- 503 demyelinating diseases of the central nervous system: A systematic review. Multiple
- 504 Sclerosis and Related Disorders. 2021;50:102800.
- 505 5. Centonze D, Rocca MA, Gasperini C, Kappos L, Hartung H-P, Magyari M, et al.

506 Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert

- consensus. Journal of Neurology. 2021;268(11):3961-8.
- 508 6. Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, et al.
- 509 Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
- 510 Annals of Neurology. 2021;89(4):780-9.
- 511 7. Sormani MP, Salvetti M, Labauge P, Schiavetti I, Zephir H, Carmisciano L, et al.
- 512 DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Annals of
- 513 Clinical and Translational Neurology. 2021;8(8):1738-44.
- 514 8. Salter A, Fox RJ, Newsome SD, Halper J, Li DKB, Kanellis P, et al. Outcomes and
- 515 Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of

516 Patients With Multiple Sclerosis. JAMA Neurology. 2021;78(6):699-708.

- 517 9. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection
- 518 Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab,
- 519 Rituximab, and Injectable Therapies. JAMA Neurology. 2020;77(2):184-91.
- 520 10. Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, et al. Rituximab in
- 521 multiple sclerosis. A retrospective observational study on safety and efficacy.
- 522 2016;87(20):2074-81.

- 523 11. Zhao Z, Ma C-L, Gu Z-C, Dong Y, Lv Y, Zhong M-K. Incidence and Risk of Infection
- 524 Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and
- 525 Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials. Frontiers in
- 526 Immunology. 2021;12.
- 527 12. Ghadiri F, Sahraian MA, Azimi A, Moghadasi AN. The study of COVID-19 infection
- 528 following vaccination in patients with multiple sclerosis. Mult Scler Relat Disord.
- 529 2022;57:103363.
- 13. Dreyer-Alster S, Menascu S, Mandel M, Shirbint E, Magalashvili D, Dolev M, et al.
- 531 COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the
- 532 third booster dose. J Neurol Sci. 2022;434:120155.
- 533 14. Tallantyre EC, Vickaryous N, Anderson V, Asardag AN, Baker D, Bestwick J, et al.
- 534 COVID-19 Vaccine Response in People with Multiple Sclerosis. Ann Neurol. 2022;91(1):89-
- 535 100.
- 536 15. König M, Lorentzen ÅR, Torgauten HM, Tran TT, Schikora-Rustad S, Vaage EB, et
- al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance
- 538 of time since last rituximab infusion and first experience from sporadic revaccinations.
- 539 Journal of Neurology, Neurosurgery & amp; Psychiatry. 2021; jnnp-2021-327612.
- 540 16. Katz JD, Bouley AJ, Jungquist RM, Douglas EA, O'Shea IL, Lathi ES. Humoral and T-
- 541 cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with
- ocrelizumab. Mult Scler Relat Disord. 2022;57:103382.
- 543 17. Apostolidis SA, Kakara M, Painter MM, Goel RR, Mathew D, Lenzi K, et al. Cellular
- and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with
- 545 multiple sclerosis on anti-CD20 therapy. Nature Medicine. 2021;27(11):1990-2001.
- 18. Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of
- 547 ocrelizumab on vaccine responses in patients with multiple sclerosis. The VELOCE study.
- 548 2020;95(14):e1999-e2008.

549	19.	Türkoğlu R, Baliç N, Kızılay T, Erol R, Akbayır E, Yılmaz V, et al. Fingolimod impairs
550	inactiv	vated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in
551	perso	ns with multiple sclerosis. Mult Scler Relat Disord. 2022;58:103524.
552	20.	Altieri M, Capuano R, Conte M, Donnarumma G, Grimaldi E, Coppola N, et al. Six-
553	month	humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple
554	sclerc	sis treated with natalizumab. Neurol Sci. 2022.
555	21.	lannetta M, Landi D, Cola G, Campogiani L, Malagnino V, Teti E, et al. B- and T-Cell
556	Respo	onses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving
557	Disea	se Modifying Therapies: Immunological Patterns and Clinical Implications. Front
558	lmmu	nol. 2021;12:796482.
559	22.	Brill L, Rechtman A, Zveik O, Haham N, Levin N, Shifrin A, et al. Effect of cladribine
560	on CC	OVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in
561	patier	ts with multiple sclerosis. Mult Scler Relat Disord. 2022;57:103343.
562	23.	Ciampi E, Uribe-San-Martin R, Soler B, García L, Guzman J, Pelayo C, et al. Safety
563	and h	umoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in
564	patier	ts with Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 2022;59:103690.
565	24.	Habek M, Željko C, Savić Mlakar A, Bendelja K, Rogić D, Adamec I, et al. Humoral
566	and c	ellular immunity in convalescent and vaccinated COVID-19 people with multiple
567	sclerc	sis: Effects of disease modifying therapies. Mult Scler Relat Disord. 2022;59:103682.
568	25.	Sabatino JJ, Jr., Mittl K, Rowles WM, McPolin K, Rajan JV, Laurie MT, et al. Multiple
569	sclerc	sis therapies differentially impact SARS-CoV-2 vaccine-induced antibody and T cell
570	immu	nity and function. JCI Insight. 2022.
571	26.	Tortorella C, Aiello A, Gasperini C, Agrati C, Castilletti C, Ruggieri S, et al. Humoral-
572	and T	-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With
573	MS U	sing Different Disease-Modifying Therapies. Neurology. 2022;98(5):e541-e54.

574 27. Gadani SP, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith MD, et al.

575 Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with

576 multiple sclerosis on anti-CD20 therapy. EBioMedicine. 2021;73:103636.

577 28. Bajwa HM, Novak F, Nilsson AC, Nielsen C, Holm DK, Østergaard K, et al.

578 Persistently reduced humoral and sustained cellular immune response from first to third

579 SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients. Mult Scler

580 Relat Disord. 2022;60:103729.

581 29. König M, Torgauten HM, Tran TT, Holmøy T, Vaage JT, Lund-Johansen F, et al.

582 Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple

583 Sclerosis and Weak Immune Response After COVID-19 Vaccination. JAMA Neurol. 2022.

30. Brill L, Raposo C, Rechtman A, Zveik O, Levin N, Oiknine-Djian E, et al. Severe

585 Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple

586 Sclerosis Patients Treated with Ocrelizumab. Annals of Neurology. 2022;91(6):796-800.

587 31. Disanto G, Sacco R, Bernasconi E, Martinetti G, Keller F, Gobbi C, et al. Association

588 of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2

589 SARS-CoV-2 vaccines in patients with multiple sclerosis. JAMA neurology.

590 2021;78(12):1529-31.

591 32. Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E, Wolf DG, et al. Humoral and

592 T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated

593 With Ocrelizumab. JAMA Neurology. 2021;78(12):1510-4.

33. Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association

595 of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive

596 Multiple Sclerosis. JAMA. 2019;321(2):175-87.

597 34. Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, et al.

598 Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With

599 Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA

600 Neurology. 2021;78(10):1197-204.

35. Norwegian Institute of Public Health. Coronavirus vaccination - statistics. 2022

602 [updated 01/08/2022. Available from: https://www.fhi.no/en/id/vaccines/coronavirus-

603 immunisation-programme/coronavirus-vaccination---statistic/.

604	36.	Francis G, Ka	appos L, O'O	Connor P.	Collins W.	Tang D.	Mercier F.	et al.	Temporal

- 605 profile of lymphocyte counts and relationship with infections with fingolimod therapy. Multiple
- 606 Sclerosis Journal. 2014;20(4):471-80.
- 607 37. Sullivan R, Kilaru A, Hemmer B, Campbell Cree BA, Greenberg BM, Kundu U, et al.
- 608 COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients. Case Series.
- 609 2022;9(1):e1092.
- 38. Thomas K, Sehr T, Proschmann U, Rodriguez-Leal FA, Haase R, Ziemssen T.
- 611 Fingolimod additionally acts as immunomodulator focused on the innate immune system
- beyond its prominent effects on lymphocyte recirculation. J Neuroinflammation.
- 613 2017;14(1):41.
- 39. Leon J, Michelson DA, Olejnik J, Chowdhary K, Oh HS, Hume AJ, et al. A virus-
- specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the
- 616 immune–epithelial interface. Proceedings of the National Academy of Sciences.
- 617 2022;119(1):e2116853118.
- 40. McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple

sclerosis and other conditions. The Lancet. 2021;398(10306):1184-94.

- 41. Garjani A, Patel S, Bharkhada D, Rashid W, Coles A, Law GR, et al. Impact of mass
- 621 vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking
- 622 immunomodulatory disease-modifying therapies in England. Multiple Sclerosis and Related
- 623 Disorders. 2022;57:103458.
- 42. Schiavetti I, Cordioli C, Stromillo ML, Teresa Ferrò M, Laroni A, Cocco E, et al.
- 625 Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
- 626 Multiple Sclerosis Journal. 2022;0(0):13524585221102918.
- 43. Sormani MP, Schiavetti I, Inglese M, Carmisciano L, Laroni A, Lapucci C, et al.
- 628 Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on
- disease modifying therapies during the Delta and the Omicron waves in Italy. eBioMedicine.
- 630 2022;80:104042.

- 44. Bsteh G, Gradl C, Heschl B, Hegen H, Di Pauli F, Assar H, et al. Impact of
- 632 vaccination on COVID-19 outcome in multiple sclerosis. European Journal of Neurology.
- 633 2022;n/a(n/a).
- 45. Servellita V, Syed AM, Morris MK, Brazer N, Saldhi P, Garcia-Knight M, et al.
- 635 Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and
- 636 Delta variants. Cell. 2022;185(9):1539-48.e5.
- 46. Yu ED, Wang E, Garrigan E, Goodwin B, Sutherland A, Tarke A, et al. Development
- 638 of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection
- and COVID-19 vaccination status. Cell Host & Microbe. 2022;30(3):388-99.e3.
- 47. Liu J, Chandrashekar A, Sellers D, Barrett J, Jacob-Dolan C, Lifton M, et al. Vaccines
- elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature.
- 642 2022;603(7901):493-6.
- 48. Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, et al. Pre-
- existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature.
- 645 2022;601(7891):110-7.
- 49. Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al.
- 647 Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine.
- 648 2021;39(32):4423-8.
- 50. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
- 650 Neutralizing antibody levels are highly predictive of immune protection from symptomatic
- 651 SARS-CoV-2 infection. Nature Medicine. 2021;27(7):1205-11.
- 52 51. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al.
- 653 Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature.
- 654 2021;590(7847):630-4.
- 55 52. Tran TT, Vaage E, Mehta A, Chopra A, Kolderup A, Anthi A, et al. Multiplexed
- measurement of binding-and neutralizing antibodies to SARS- CoV-2 variants in 12.000 post-
- 657 vaccine sera2022.

658	53.	Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, et al. Humoral and
659	cellula	r immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-
660	treated	d patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol.
661	2022;4	4(3):e177-e87.
662	54.	Huang Y, Yang C, Xu X-f, Xu W, Liu S-w. Structural and functional properties of

- 663 SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta
- 664 Pharmacologica Sinica. 2020;41(9):1141-9.

665

666

#### 667 <u>Figure legends</u>

Table 1: Summary of participant characteristics. Participants are grouped by DMT. V0 indicates pre-vaccination baseline samples, V2 indicates samples taken after receiving 2 doses of vaccine, and V3 indicates samples taken after 3 doses of vaccine. Numbers of individuals per DMT group, age, sex, time since last drug treatment, vaccine types, time between sampling and the corresponding vaccine dose, and the number of participants in each group who were subsequently infected with COVID-19 >2 weeks post-vaccination.

674

675 Figure 1: Lymphocyte proportions in peripheral blood and spike-specific vaccination 676 responses in pwMS on DMTs. Individuals are grouped by DMT (healthy controls (HC), 677 alemtuzumab (ALEM)-, cladribine (CLAD)-, natalizumab (NTZ)-, fingolimod (FIN)- and 678 rituximab (RTX)-treated MS patients). (A) CD3+ lymphocyte proportions and (B) the ratio of 679 CD4:CD8 T cells in different DMT groups showed reduced frequencies of CD3+ lymphocytes 680 and CD4+ T cells in fingolimod-treated patients. Violin plots show individuals as separate 681 points, lines indicate median, IQR, and min and max. Mann-Whitney test comparing drug-682 treated groups with healthy controls, two-tailed p values were calculated, \*\*\*\* p<0.0001. (C) 683 Binding antibody units after 2 doses of vaccine. Responses below the lower limit of detection

684	are shown as 0.5 BAU/mI; titres <5 BAU/mI are considered negative, 5-20 BAU/mI as very
685	weak positives, 20-200 BAU/ml as weak positives and >200 BAU/ml as positives. (D) CD4 T $$
686	cell (CD40L+ TNF- $\alpha$ +) and (E) CD8 T cell responses (IFN- $\gamma$ + and/or TNF- $\alpha$ +) to spike
687	peptides before (V0) and after (V2) 2 doses of vaccine. Responses with 0 events are plotted
688	at 0.001% to indicate non-responses. Samples from the same individual before and after
689	vaccination are paired with a line. Patient numbers for each group are indicated along the x-
690	axis. Individuals with <1000 CD4 or CD8 T cells acquired by FACS were excluded from
691	further analysis. Statistical comparisons by Wilcoxon two-tailed paired t-tests, * p<0.05.
692	
693	Figure 2: T cell and antibody responses in rituximab- and fingolimod-treated patients after 3 <sup>rd</sup>
694	vaccine dose. Antibody responses (BAU/mI), CD4+ and CD8+ T cell responses after 3 <sup>rd</sup>

vaccine dose in rituximab-treated (A-C) and fingolimod-treated patients (D-F) (A, n=43-61);

696 B, n=21-56; C, n=21-54; D, n=13-21; E, n=6-13; F, n=6-17). Individuals with <1000 CD4+ T

697 cells acquired by FACS were excluded from this analysis. Dotted lines in (A) and (D) indicate

698 classification of antibody responses as negative or positive as described previously. For B-C

and E-F, lines on scatter plots indicate the median. Statistical analyses by Wilcoxon paired t-

tests, two-tailed p values are shown, \* p<0.05, \*\*\* p<0.001

701

702 Figure 3: Re-administration of rituximab between vaccine doses affects antibody but not T 703 cell responses. Rituximab-treated individuals were grouped by whether or not they received a dose of RTX between vaccine doses 2 and 3. (A) Antibody titres (BAU/ml) after 2<sup>nd</sup> (V2) 704 and 3<sup>rd</sup> (V3) vaccine doses for patients who did not receive RTX between vaccines (empty 705 706 boxes) (n= 20-32) and patients who did receive RTX between vaccines (grey boxes) (n=23-707 30). (B) CD4 T cell and (C) CD8 T cell responses without stimulation (unstim) or to SARS-CoV-2 spike or CMV peptides after 3<sup>rd</sup> vaccine dose for patients without (n=28) or with RTX 708 709 administration (n=28) between vaccine doses, as previously. Statistical analyses for paired

responses by Wilcoxon t test, unpaired responses by Mann-Whitney, two-tailed p values are
shown, \* p<0.05, \*\* p<0.01.</li>

712

713	Figure 4: T cell responses to the Delta and Omicron SARS-CoV-2 variants after three
714	vaccine doses. Schematic of mutated regions in the Alpha, Delta and Omicron regions
715	stimulated by peptides (A). The SARS-CoV-2 spike protein is 1273 amino acids (aa) long,
716	consisting of the signal peptide, S1 and S2 subunits; the receptor binding domain (RBD) in
717	S1 is indicated in red (54). Regions covered by the SARS-CoV-2 Prot_S (WT) peptide used
718	for AIM assays are shown for reference. The control and mutant peptides for each variant
719	cover the same loci but with the mutated (mutant) or Wuhan-Hu-1 variant (control). Amino
720	acid mutations are listed in Methods. PBMCs from rituximab-treated patients after a 3 <sup>rd</sup>
721	vaccine dose were stimulated with spike peptide pools from the mutated regions (blue
722	circles) of the Alpha (n=29), Delta (n=41) and Omicron VOC (n=21) and the same regions of
723	the WT sequence (empty circles) and the CD4+ (B) and CD8+ (C) T cell responses were
724	compared. Statistical differences were calculated by Wilcoxon paired t tests. * p<0.05, **
725	p<0.01

			Alemtuzumab		Cladribine		Natalizumab		Fingolimod			Rituximab			Healthy controls	
			V0	V2	V0	V2	V0	V2	V0	V2	V3	V0	V2	V3	V0	V2
	n		11	11	8	8	10	8	12	18	20	5	13	63	15	15
medRx (wh	Previous COVID-19 iv preprint doi: https://doi.o ich was court free by r	rg/10.1101/2022.08.25.2227 beer review) is the author/fur	9202; this version der, who has gre	n posted August 25. anted medRxiv a lic	2022. The copyri	ght holder for this depeprint in perpe	preprint tuity. 0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (80.0)	5 (38.5)	3 (4.8)		0
		It is made available under	a CC-BY-NC-N	7.4 International li	cense . 42	2.4	37.0	37.0	41.8	45.3	47.7	29.6	39.1	43.3		46
	Age (years)	Mean	3	5.3	43	1.5	38.1	37.8	41.1	45.1	47.0	31.1	41.1	46.0	4	6.0
		Range	22 - 47.5		34.0 - 47.3		26.3 - 51.6	26.3 - 51.6	33.1 - 49.0	33.1 - 60.4	30.5 - 66.0	18.3 - 47.3	18.3 - 76.9	22.1 - 76.9	25.0	- 63.0
	Sex	Female (%)	8 (	72.7)	8 (2	100)	7 (70.0)	6 (75.0)	6 (50.0)	8 (44.4)	11 (55.0)	3 (60.0)	9 (69.2)	53 (84.1)	12	(80.0)
	Time since last	Median	164.1	165.9	31.3	32.5	0	0.93				5.86	14.5	24.7/8.43 <sup>b</sup>		
	drug treatment	Mean	156.2	157.9	36.2	38.9	-1.7 <sup>a</sup>	1.89				9.37	18.5	28.1/8.31 <sup>b</sup>		
	(weeks)	Range	70.3 - 252.1	71.7 - 252.4	3.0 - 78.4	5.14 - 83.4	-4.57 - 5.14 <sup>a</sup>	0.29 - 6.0		Taken daily		-0.7 - 31.9 <sup>a</sup>	8.43 - 46.0	17.0 - 63.0/1.86 - 19.7 <sup>b</sup>	r	n/a
		BNT162b2		9		6		6		12	14		7	52 <sup>d</sup>		0
	Vaccine type - first	mRNA-1273		2		2		2		6	6		3	8		9
	dose (n)	ChAdOx1-S		0		0		0		0	0		0	3		6
		COVID-19 infection		0		0		0		0	0	4	3 <sup>c</sup>	2 <sup>d</sup>		0
	Vaccine type -	BNT162b2		9		6		6		12	14		10	55		6
	second dose (n)	mRNA-1273		2		2		2		6	6		3	8		9
	Vaccine type -	BNT162b2									6			12		
	third dose (n)	mRNA-1273	r	n/a	n	/a	n/	'a	n,	/a	14	n,	/a	51	n	n/a
	Time between	Median		11		12		12		13	28.5		38	23		10
	sample and last	Mean		11 0		10.4		12.0		22 G	20.2		22 E	25.6		10.2
	vaccine dose			11.2		19.4		15.9		22.0	29.5		55.5	25.0		10.5
	(days)	Kange	n/a	8 - 15	n/a	7 - 73	n/a	9 - 26	n/a	7 - 49	20 - 43	n/a	8 - 71	20 - 42	n/a	8 - 16
	Covid infection >14 days post-full															
	vaccination (%)		n/a	2 (18.2)	n/a	3 (37.5)	n/a	3 (37.5)	n/a	n/a	2 (10.0)	n/a	n/a	14 (22.2)	n/a	5 (33.3)

<sup>a</sup> Negative time values indicate drug was administered after sample was taken

<sup>b</sup> Individuals are split into groups who last received RTX prior to V0 and those who received RTX between V2 and V3 (see Fig. 3)

<sup>c</sup> Some individuals were infected with COVID-19 at baseline, which was treated as analogous to a first vaccine dose

<sup>d</sup> Some individuals with prior COVID-19 infections still received a 'first' vaccine dose of BNT162b2 and are represented twice



![](_page_30_Figure_0.jpeg)

CMN

CMN

![](_page_31_Figure_0.jpeg)

<sup>□</sup> No RTX between V2-V3

**RTX between V2-V3** 

![](_page_32_Figure_0.jpeg)